AZTEC-CF
Details
- Therapeutic approach
- Anti-Infective
- Trial status
- Closed with results Participating Centres
- Trials Tracker ID
- TT001726
- Last updated
- 24/02/2020
Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis
Study detailsThis study aims to investigate whether it is safe and effective to use one inhaled antibiotic and one via a drip, instead of the current standard of practice of two antibiotics via a drip. Participants will receive the two different treatments the next two occasions they need to be admitted to Liverpool Heart & Chest Hospital with a chest infection. On one admission they will receive two IV antibiotics, on the other admission they will receive one IV antibiotic and inhaled aztreonam (known as Cayston®). The order they receive each treatment will be picked at random. Participants will have measurements taken including lung function tests, blood tests, CF quality of life questionnaires, and sputum samples will be sent to the University of Liverpool for advanced analysis of the effect each treatment has on bugs in the lung. It is hoped that this study may help provide more information toward a much needed expansion of therapeutic options available in CF.
- Phase
- Phase 4
- Length of participation
- 2 exacerbations
- Recruitment target
- 16
- CF sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
- CF sponsor type
- Academic
Who can take part?
- Age range
- 18 years and older
- Including people
18 - 65 years old Pseudomonas aeruginosa in last 6 months
Pseudomonas aeruginosa in last 6 months
FEV1 25-75%- Excluding people
Already prescribed regular Cayston
Previous organ transplant
Documented allergy to beta-lactam antibiotics or IV Colistin
Get in touch